Cargando…

ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models

Advances in oral SERDs development so far have been confined to nonsteroidal molecules such as those containing a cinnamic acid moiety, which are in earlystage clinical evaluation. ZB716 was previously reported as an orally bioavailable SERD structurally analogous to fulvestrant. In this study, we e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Shanchun, Zhang, Changde, Bratton, Melyssa, Mottamal, Madhusoodanan, Liu, Jiawang, Ma, Peng, Zheng, Shilong, Zhong, Qiu, Yang, Lin, Wiese, Thomas E., Wu, Yong, Ellis, Matthew J., Matossian, Margarite, Burow, Matthew E., Miele, Lucio, Houtman, René, Wang, Guangdi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805526/ https://www.ncbi.nlm.nih.gov/pubmed/29467940 http://dx.doi.org/10.18632/oncotarget.24023

Ejemplares similares

Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD)
por: Zhang, Changde, et al.
Publicado: (2017)

Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies
por: Liu, Jiawang, et al.
Publicado: (2021)

SAT-341 Pharmacology and Metabolism of GLL398 an Oral Selective Estrogen Receptor Degrader for Endocrine Therapy of Breast Cancer
por: Guo, Shanchun, et al.
Publicado: (2019)

Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer
por: Kang, Borui, et al.
Publicado: (2023)

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
por: Mottamal, Madhusoodanan, et al.
Publicado: (2015)

Design, Synthesis, and Biological Evaluation of Novel Pyridine-Bridged Analogues of Combretastatin-A4 as Anticancer Agents
por: Zheng, Shilong, et al.
Publicado: (2014)

Obesity-Altered Adipose Stem Cells Promote ER(+) Breast Cancer Metastasis through Estrogen Independent Pathways
por: Sabol, Rachel A., et al.
Publicado: (2019)

From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target
por: Mottamal, Madhusoodanan, et al.
Publicado: (2021)

Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models
por: Sabol, Rachel A., et al.
Publicado: (2019)

Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability
por: Zhang, Changde, et al.
Publicado: (2019)

The GBT-SerDes ASIC prototype
por: Moreira, P, et al.
Publicado: (2010)

High speed serdes devices and applications
por: Stauffer, David R, et al.
Publicado: (2008)

Patient-Derived Xenografts as an Innovative Surrogate Tumor Model for the Investigation of Health Disparities in Triple Negative Breast Cancer
por: Matossian, Margarite D., et al.
Publicado: (2020)

Liver Kinase B1 Regulates Remodeling of the Tumor Microenvironment in Triple-Negative Breast Cancer
por: King, Connor T., et al.
Publicado: (2022)

Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling
por: Bhatt, Akshita B., et al.
Publicado: (2021)

Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
por: Matossian, Margarite D., et al.
Publicado: (2019)

Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status
por: Zhong, Qiu, et al.
Publicado: (2015)

Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy
por: Dong, Shengli, et al.
Publicado: (2023)

Modification and Biological Evaluation of Thiazole Derivatives as Novel Inhibitors of Metastatic Cancer Cell Migration and Invasion
por: Zheng, Shilong, et al.
Publicado: (2014)

Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration
por: Zhou, Changhua, et al.
Publicado: (2012)

Functional validation of ZbFAD2 and ZbFAD3 in the alkylamide biosynthesis pathway from Zanthoxylum bungeanum Maxim
por: Zhang, Jie, et al.
Publicado: (2022)

The Organochlorine o,p’-DDT Plays a Role in Coactivator-Mediated MAPK Crosstalk in MCF-7 Breast Cancer Cells
por: Bratton, Melyssa R., et al.
Publicado: (2012)

A custodial symmetry for $Zb\overline{\b}$
por: Agashe, K, et al.
Publicado: (2006)

Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment
por: Nguyen, Khoa, et al.
Publicado: (2021)

Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status
por: Downton, Teesha, et al.
Publicado: (2022)

Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer
por: Bhatt, Akshita B., et al.
Publicado: (2021)

Insulin-Like Growth Factor-1 Signaling Regulates miRNA Expression in MCF-7 Breast Cancer Cell Line
por: Martin, Elizabeth C., et al.
Publicado: (2012)

Ceritinib is a novel triple negative breast cancer therapeutic agent
por: Dong, Shengli, et al.
Publicado: (2022)

Effect of a brain‐penetrant selective estrogen receptor degrader (SERD) on binge drinking in female mice
por: Chen, Hu, et al.
Publicado: (2022)

ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer
por: Hoang, Van T., et al.
Publicado: (2020)

Breast Tumor Analysis Using Shifted-Excitation Raman Difference Spectroscopy (SERDS)
por: Gebrekidan, Medhanie Tesfay, et al.
Publicado: (2018)

The Zb$\overline{b}$ vertex: implications for the Standard Model and beyond
por: Cornet, F, et al.
Publicado: (1994)

Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16
por: Tyurenkov, Ivan N., et al.
Publicado: (2018)

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells
por: Fanning, Sean W, et al.
Publicado: (2018)

The In Vitro Effects of Pentamidine Isethionate on Coagulation and Fibrinolysis
por: Al-Horani, Rami A., et al.
Publicado: (2019)

Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia
por: Kar, Srabani, et al.
Publicado: (2020)

Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model
por: Matossian, Margarite D., et al.
Publicado: (2018)

Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant-resistant phenotype in breast cancer cells
por: Matossian, Margarite D., et al.
Publicado: (2021)

Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes
por: Matossian, Margarite D., et al.
Publicado: (2017)

Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways
por: Hossain, Fokhrul, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dqkeuf0kg48k9085kvmn8m7jh1